Abstract:
본 발명은 인간 과립구 콜로니 자극 인자(G-CSF)의 변이체를 포함하는 허혈성 질환 치료용 약학 조성물에 관한 것으로, 더욱 상세하게는 인간 과립구 콜로니 자극인자(G-CSF)의 아미노산 잔기 140번째 페닐알라닌(Phenylalanine, F)이 아스파라긴 (Asparagine, N)으로 치환되어 당쇄화가 일어나도록 아미노산 변형된 인간 과립구 콜로니 자극 인자(G-CSF)의 변이체를 포함하는 허혈성 질환 치료용 약학 조성물에 관한 것이다.
Abstract:
PURPOSE: A mutant human G-CSF with increased biological activity is provided to ensure superior biological activity and excellent economic effect with low dosage. CONSTITUTION: A mutant human G-CSF has amino acid modification by N-glycosylateion by formation of Asn-X-Ser/Thr(N-X-S/T) sequence in an amino acid residues: T1-P10 (T1-P-L-Q-P-A-S-S-L-P10); K40-Q70 (K40-L-C-H-P-E-E-L-V-L-L-G-H-S-L-G-I-P-W-A-P-L-S-S-C-P-S-Q-A-L-Q70); or L124-S142 (L124-G-M-A-P-A-L-Q-P-T-Q-G-A-M-P-A-F-A-S142). A pharmaceutical composition contains the mutant human G-CSF.
Abstract:
PURPOSE: An apparatus for separating fine solids for reducing contaminants of wastewater is provided in which wastewater bearing organic materials including various animal excretions, animal and plant residues, etc. can be composted without using moisture controlling agents. CONSTITUTION: The apparatus comprises an excrementitious slurry supplying pipe (32) installed at the upper part of the one side of an aeration tank (30) for supplying the slurry according to the control of an excrementitious slurry supply control part (31); an air supply control part (34) connected to an air supplying passage (33) located at the water bottom part of the aeration tank; a screw type auger (35) installed from the lower part of the aeration tank to over the surface of the wastewater and equipped with a solid discharging hole (36); an ultra-low speed reduction unit (37) installed at the end part of the screw type auger for blocking a slurry counterflow; an inlet pipe (41) installed from the upper part of the aeration tank to the lower part of a settling tank (40) so that the floating liquid passing through the aeration process at the aeration tank is flown into the settling tank; a reverse osmosis membrane forming part (42) installed by being floated on the upper part of the settling tank; a return pipe (43) connected to a power return part (44) at the lower part of the settling tank for returning a sediment of the settling tank to the aeration tank; and a water treatment system connecting pipe (45) installed at the upper part of the one side of the settling tank for guiding the floating liquid passing through the reverse osmosis membrane forming part to a water treatment system (50) by a transferring power part (46).
Abstract:
PURPOSE: Provided are a microbial composition of a fermenting agent for the bioremediation of malodorants and its manufacturing method. The microbial composition further contains feed additives, such as copper, rice bran and zeolite, to increase a deodorizing effect. CONSTITUTION: The microbial composition of a fermenting agent for the bioremediation of malodorants comprises at least one of Aspergillus niger, Aspergillus oryzae, Penicillium spp., Mucor spp., Trichoderma viride, Cephallosporium acremonium and Issatchenkia orientalis; at least one of Candida spp., and Arthrobacter spp., Nocardia spp.; at least one of Bacillus subtilis CH-10, Bacillus mesentericus, Bacillus megaterium, Bacillus licheniformis NLRI-33, Bacillus thuringiensis, and bacillus circulans; at least one of Thermoactinomyces sp. and/or Thermomonspora spp.; at least one of Streptomyces griseus, Streptomyces globisporius, and Streptomyces flavus; and at least one of Pseudomonas putida NLRI-X50, Corynebacterium spp., Staphylococcus lentus, and Micrococcus lylae.
Abstract:
PURPOSE: Provided are a microbial composition of a fermenting agent for the bioremediation of malodorants and its manufacturing method. The microbial composition further contains feed additives, such as copper, rice bran and zeolite, to increase a deodorizing effect. CONSTITUTION: The microbial composition of a fermenting agent for the bioremediation of malodorants comprises at least one of Aspergillus niger, Aspergillus oryzae, Penicillium spp., Mucor spp., Trichoderma viride, Cephallosporium acremonium and Issatchenkia orientalis; at least one of Candida spp., and Arthrobacter spp., Nocardia spp.; at least one of Bacillus subtilis CH-10, Bacillus mesentericus, Bacillus megaterium, Bacillus licheniformis NLRI-33, Bacillus thuringiensis, and bacillus circulans; at least one of Thermoactinomyces sp. and/or Thermomonspora spp.; at least one of Streptomyces griseus, Streptomyces globisporius, and Streptomyces flavus; and at least one of Pseudomonas putida NLRI-X50, Corynebacterium spp., Staphylococcus lentus, and Micrococcus lylae.
Abstract:
PURPOSE: A pharmaceutical composition containing human G-CSF mutant is provided to reduce administration amount and number. CONSTITUTION: A pharmaceutical composition for treating ischemic diseases contains the G-CSF mutant which is modified by substitution of 140th amino acid residue of human G-CSF, from phenylalanine(F) to asparagine(N). The human G-CSF is G-CSFb. The pharmaceutical composition further contains a carrier or excipient. The pharmaceutical composition also contains suspension, stabilizing agent, isotonizing agent, preservative, anti-adsorbing agent, surfactant, pH adjusting agent, analgesia agent, or anti-oxidant agent.